5-Carboxylcytosine levels are elevated in human breast cancers and gliomas

Maria Eleftheriou1, Ana Jimenez Pascual1, Lee M. Wheldon2, Christina Perry7, Abdul Kadir Abakir1,8, Arvind Arora3, Andrew D. Johnson4, Dorothee T. Auer5, Ian O. Ellis6, Srinivasan Madhusudan7 and Alexey Ruzov1*

Abstract

Background: DNA methylation (5-methylcytosine (5mC)) patterns are often altered in cancers. Ten-eleven translocation (Tet) proteins oxidise 5mC to 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC). In addition to their presumptive specific biological roles, these oxidised forms of 5mC may serve as intermediates in demethylation process. According to several reports, 5hmC levels are strongly decreased in cancers; however, the distribution of 5fC and 5caC in malignant tissue has not been studied.

Findings: Here, we examine the levels of 5hmC and 5caC in 28 samples of normal breast tissue, 59 samples of invasive human breast cancer and 74 samples of gliomas using immunohistochemistry. In agreement with previous reports, we show that 71% of normal breast samples exhibit strong 5hmC signal, compared with only 18% of breast cancer samples with equivalent levels of 5hmC staining. Unexpectedly, although 5caC is not detectable in normal breast tissue, 27% of breast cancer samples exhibit significant staining for this modification (p < 0.001). Surprisingly, the presence of immunohistochemically detectable 5caC is not associated with the intensity of 5hmC signal in breast cancer tissue. In gliomas, we show that 5caC is detectable in 45% of tumours.

Conclusions: We demonstrate that, unlike 5hmC, the levels of 5caC are elevated in a proportion of breast cancers and gliomas. Our results reveal another level of complexity to the cancer epigenome, suggesting that active demethylation and/or 5caC-dependent transcriptional regulation are pre-activated in some tumours and may contribute to their pathogenesis. Larger studies to evaluate the clinicopathological significance of 5caC in cancers are warranted.

Keywords: DNA methylation, 5-hydroxymethylcytosine, 5-carboxylcytosine, Carcinogenesis, Breast cancer, Immunohistochemistry

Findings

Background

DNA methylation (5-methylcytosine (5mC)) is an epigenetic modification, which contributes to the regulation of gene expression in a wide range of biological contexts [1]. The patterns of DNA methylation are altered in a range of cancers [1, 2]. Moreover, hypermethylation of promoters of tumour-suppressor genes has been identified as one of the causes of cancer progression [3].

Ten-eleven translocation (Tet) proteins (Tet1/2/3) contain a C-terminal catalytic dioxygenase domain that oxidises 5mC to 5-hydroxymethylcytosine (5hmC) and further to 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC) [4–6]. A number of recent studies suggest that 5hmC plays a specific role in both transcriptional regulation and DNA demethylation in different biological settings [7, 8]. Importantly, 5hmC is strongly depleted in human cancers [9, 10] and its loss is accompanied with malignant cellular transformation [11, 12].

5hmC has recently attracted considerable attention from cancer biologists; however, the distribution of the
two other oxidised forms of 5mC (5fC and 5caC) in malignant tissue has not been studied. Nevertheless, both these marks can be recognised and excised from DNA by thymine-DNA glycosylase (TDG) followed by regeneration of non-modified cytosine via base-excision repair (BER) pathway leading to active Tet/TDG-dependent demethylation of certain genomic regions [5, 6, 13]. Since demethylation of promoters of tumour-suppressor genes has been implicated in tumorigenesis [3], elucidating potential roles of these modifications in cancers would be important for understanding the mechanisms of cancer progression.

We previously showed that although both 5fC and 5caC are immunochemically detectable in mammalian post-implantation embryos with similar patterns of spatial distribution, the intensity of 5fC signal is always considerably weaker than that of 5caC likely due to a lower sensitivity of the 5fC antibody [14]. Thus, in this study, we focused our analysis on 5caC aiming to determine the global levels of this mark in human breast cancers and gliomas.

Methods

Patients and tissue samples

Paraffin-embedded formaldehyde-fixed tissue microarray blocks were used for 5hmC and 5caC immunochemical detection in breast cancers. The microarray blocks contained 97 cores with 59 samples of invasive breast cancer tissues with the rest of the cores representing normal breast tissue. The breast cancer tissue samples were invasive ductal carcinomas from patients who underwent surgery for early stage breast cancers. All tumours were reviewed by expert pathologist at the Nottingham University Hospitals. All tumours were derived from Caucasian patients diagnosed with breast cancer lacking any known germ-line mutations in BRCA1 or BRCA2. The ‘normal’ samples were tumour-associated normal breast tissue removed at the time of definite surgery in the Caucasian patients diagnosed with breast cancer lacking any known germ-line mutations in BRCA1 or BRCA2. Ethical approval for the breast cancer study was granted by the Nottingham Research Ethics Committee 2 under the title ‘Development of a molecular genetic classification of breast cancer’ (C202313). Examination of 5caC distribution in gliomas was performed using 76 paraffin-embedded tumour sections from patients treated at Nottingham University Hospitals between the years 2005 and 2011. Of the glioma patients, 45/74 (60.8 %) were male. The median age of patients at inclusion in the study was 47 years (range 22–81 years). Twenty-seven percent (20/74) of the patients were diagnosed with a low grade glioma (all grade 2). Of the 54 high grade gliomas included in the study, 15/54 (27.8 %) were grade 3 tumours and 39/54 (72.2 %) were grade 4 tumours. In patients with low grade glioma, 12/20 (60.0 %) were male and the median age at inclusion in the study was 33.5 years (range 25–57 years). The median age at study inclusion was 54.5 years (range 22–81 years), and 33/54 (61.1 %) patients with high grade glioma were male. All the samples have been examined by an expert neuropathologist. All the patients were referred from Nottingham, Leicester, Lincoln and Derby, Leicestershire, Northamptonshire and Rutland Research Ethics committee. This study has been approved by the Regional Ethics Committee (reference number 08/H0406/102). Biomax US tissue microarray (BN1002a) was used for fluorescent immunohistochemistry of normal breast tissue.

Immunohistochemistry, microscopy, scoring and statistical analysis

3,3′-Diaminobenzidine (DAB)-based immunohistochemistry was performed using the Novolink kit polymer detection system (Cat. no.RE7280-K, Leica) following the manufacturer’s instructions. The slides were de-waxed and rehydrated according to the standard procedures and incubated in the antigen retrieval citrate solution heated to close to boiling for 20 min. Anti-5hmC (cat. no. 39791; Active Motif, 1:2000 dilution) and anti-5caC (cat. no. 61225; Active Motif, 1:1000 dilution) rabbit polyclonal antibodies were diluted in Leica diluent (cat. no. AR9352) and incubated with the slides for 1 h at room temperature. After incubation with primary antibodies, the slides were washed in TBS and incubated in post primary block solution for 30 min, followed by washes in TBS and incubation with the polymer solution for 5 min. Haematoxylin was used for nuclei visualisation. 5hmC signal was evaluated as undetectable (0), weak (1), moderate (2) or strong (3). 5caC staining intensity was assessed as negative (0) or positive (1). Paraffin-embedded formaldehyde-fixed 12.5 dpc murine embryonic tissue was used as a positive control for 5hmC/5caC immunostaining. Images were obtained using a Nikon eclipse 80i microscope. Immunofluorescence immunohistochemistry and confocal microscopy was performed as described in [14]. Control staining without primary antibody produced no detectable signal. Statistical significance of the differences between the distributions of 5hmC and 5caC was determined by the ANOVA single factor test. Chi-squared tests were used to examine associations between two categorical variables.

Results

We have previously extensively used fluorescent immunohistochemistry for detection of both 5hmC and 5caC in mammalian and amphibian tissues [14–16]. Moreover, our protocol for immunohistochemical detection of 5caC was validated by mass spectrometric identification of the
modified cytosine bases [14]. To compare DAB-based and fluorescence-based protocols for 5hmC/5caC immuno-staining, we initially performed detection of 5hmC and 5caC in mouse embryonic and adult brain tissues using the two immunostaining techniques (Fig. 1a–e). In agreement with our previous results [14], 5caC was detectable in 12.5 days post coitum (dpc) but not in the adult mouse brain by both methods (Fig. 1a–c). Furthermore, whereas 5hmC staining was fairly uniform in 12.5 dpc mouse brain, both DAB-based and fluorescent immunohistochemistry produced identical characteristic patterns of 5caC distribution in embryonic brain tissue, with staining intensity varying in the cells differentiating towards different lineages [15] (Fig. 1a, c–d). In addition, we obtained identical results from 5hmC and 5caC immunostaining of normal human breast tissue using both versions of immunohistochemistry. Thus, whereas 5hmC staining of these samples was relatively high, 5caC was immunochemically undetectable in breast tissue samples (Fig. 2a, b).

Since we obtained identical results using both staining techniques, we decided to employ DAB-based immunohistochemistry for 5hmC/5caC detection in breast cancers. Initially, we examined the levels of 5caC in 59 samples of invasive human breast cancers and 28 samples of normal breast tissue. Although we could not detect any 5caC staining in normal breast tissue samples, a significant number of cancer samples (28 %, p < 0.001) exhibited evident 5caC signal (Figs. 2c, d). In contrast, and in agreement with previous studies [9, 10], 71 % of normal breast samples exhibited strong 5hmC signal, whereas only 18 % of breast cancer samples had comparable levels of 5hmC staining. Thus, 5hmC staining was very weak in 36 % and significantly decreased in 46 % of cancer samples (Fig. 2e, f). Surprisingly, the presence of immunochemically detectable 5caC was not associated...
Fig. 2 (See legend on next page.)

Eleftheriou et al. Clinical Epigenetics (2015) 7:88
with the levels of 5hmC immunostaining in the corresponding samples of malignant breast tissue (Fig. 2f).

To extend our study with another type of cancer, we performed immunochemical detection of 5caC in 74 samples of glioma tissue. Analogous to breast cancers, this modification was detectable in 40 % of low and 46.3 % of high grade gliomas (Fig. 3a, b). Notably, the presence of 5caC was not associated with glioma grade (Fig. 3b).

Discussion

In one of the first studies reporting decreased levels of 5hmC in malignant tissue, it has been noted that the depleted 5hmC content did not correlate with the levels of Tet1/2/3 expression in a number of tumours [10]. Correspondingly, here, we show that the levels of 5caC are elevated in a considerable fraction of breast cancers we analysed, including the tumour samples producing low intensity of 5hmC staining. This suggests that, at least in some cancers, depleted 5hmC may not necessarily indicate low degrees of Tet-dependent 5mC oxidation. In contrast, it is likely that Tet1/2/3 proteins are pre-activated in certain cancer-related settings leading to the preferential oxidation of 5mC to 5fC/5caC instead of 5hmC. In this context, the presence of high 5caC levels in cancer tissue may point at intensified ratios of active demethylation or, alternatively, at repression of components of BER machinery implicated into removal of this mark from DNA [5, 6, 13]. Thus, both active remodelling of DNA methylation patterns and 5caC-dependent transcriptional regulation may participate in aberrant nuclear reprogramming associated with pathogenesis of cancers [2] adding another layer of complexity to the epigenetic landscape of this disease.

Since the large body of experimental evidence have previously indicated that 5hmC content is decreased in cancers [9–12], it has been counterintuitive to search for more oxidised forms of 5mC such as 5fC/5caC in cancer-related contexts. With an exception of a recent report, which did not find any significant difference in 5caC content between the cancer patient-derived and healthy control blood samples [17], no attempt has been made to systematically assess the global 5caC levels in tumour tissue to date. Therefore, our observation that 5caC and, potentially, DNA demethylation, is elevated in some tumours represents an important beginning for deciphering the roles of this mark in carcinogenesis and opens an avenue for further 5fC/5caC-related studies in
cancer systems. Future investigations on genomic distributions of 5fC/5caC in tumour-derived cell lines and larger studies on different types of cancers are necessary to evaluate the functions and clinicopathological significance of immunochemically detectable 5caC in tumour tissue.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
ME, AJP, AbAb, ADJ, CP and AA contributed to the immunostaining experiments, light microscopy and statistical analysis. LMW performed confocal microscopy. DTA and IOE participated in collection of the samples and the study’s design and coordination. AR and SM conceived the study, participated in its design and coordination and drafted the manuscript together with CP. All authors read and approved the final manuscript.

Acknowledgements
The work was supported by the MSc course in Stem Cell Technology (University of Nottingham) and by Medical Research Council (MR/L001047/1 to ADJ).

Author details
1 Division of Cancer and Stem Cells, School of Medicine, Centre for Biomolecular Sciences, University of Nottingham, University Park, Nottingham NG7 2RD, UK. 2 Medical Molecular Sciences, Centre for Biomolecular Sciences, University of Nottingham, University Park, Nottingham NG7 2QD, UK. 3 Department of Oncology, Nottingham University Hospitals, Nottingham NG5 1PB, UK. 4 School of Life Sciences, University of Nottingham, University Park, Nottingham NG7 2RD, UK. 5 Department of Academic Radiology, Queen’s Medical Centre, Nottingham University Hospitals, University of Nottingham, Nottingham NG7 2UH, UK. 6 Department of Pathology, Division of Cancer and Stem Cells, School of Medicine, University of Nottingham, Nottingham NG51PB, UK. 7 Academic Unit of Oncology, Division of Cancer and Stem Cells, School of Medicine, University of Nottingham, Nottingham NG51PB, UK. 8 Present address: Lab de Neurophysiologie, Université libre de Bruxelles, Campus Erasme CP 601, Bldg C Room C3-143, 808, Route de Lennik, B-1070 Brussels, Belgium.

Received: 7 May 2015 Accepted: 24 July 2015
Published online: 21 August 2015

References
1. Schübeler D. Function and information content of DNA methylation. Nature. 2015;534:321–6.
2. Godding CR, Pei D, Lu X. Cancer: pathological nuclear reprogramming? Nat Rev Cancer. 2014;14:568–73.
3. Ehrlich M, Lacey M. DNA hypomethylation and hemimethylation in cancer. Adv Exp Med Biol. 2013;754:31–56.
4. Tahiliani M, Koh KP, Shen Y, Pastor WA, Bandukwala H, Brudno Y, et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science. 2009;5929:930–5.
5. He YF, Li BZ, Li Z, Liu P, Wang Y, Tang Q, et al. Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA. Science. 2011;6047:1303–7.
6. Ito S, Shen L, Dai Q, Wu SC, Collins LB, Swenberg JA, et al. Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. Science. 2011;6047:1300–3.
7. Ficz G, Hore TA, Santos F, Lee HJ, Dean W, Arand J, et al. FGF signaling inhibition in ESCs drives rapid genome-wide demethylation to the epigenetic ground state of pluripotency. Cell Stem Cell. 2013;13:351–9.
8. Iuliano M, Ficz G, Olesy D, Raiber EA, Bachman M, Booth MJ, et al. A screen for hydroxymethylcytosine and formylcytosine binding proteins suggests functions in transcription and chromatin regulation. Genome Biol. 2013;14R119.
9. Häffner MC, Chaux A, Meeker AK, Esopi DM, Gerber J, Pellakuru LG, et al. Global S-hydroxymethylcytosine content is significantly reduced in tissue stem/progenitor cell compartments and in human cancers. Oncotarget. 2011;2:627–37.
10. Jin SG, Jiang Y, Qiu R, Rauch TA, Wang Y, Schackert G, et al. S-Hydroxymethylcytosine is strongly depleted in human cancers but its levels do not correlate with IDH1 mutations. Cancer Res. 2011;71:7360–5.
11. Kudo Y, Tateishi K, Yamamoto K, Yamamoto S, Asaoka Y, Iijichi H, et al. Loss of S-hydroxymethylcytosine is accompanied with malignant cellular transformation. Cancer Sci. 2012;103:670–6.
12. Lian CG, Xu Y, Cao C, Wu F, Larson A, Dresser K, et al. Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma. Cell. 2012;150:1135–46.
13. Matti A, Drohat AC. Thymine DNA glycosylase can rapidly excise 5-formylcytosine and 5-carboxylcytosine: potential implications for active demethylation of CpG sites. J Biol Chem. 2011;286:35334–8.
14. Wheldon LM, Abakir A, Ferjentsz Z, Dudnakova T, Strohlauecker S, Christie D, et al. Transient accumulation of 5-carboxylcytosine indicates involvement of active demethylation in lineage specification of neural stem cells. Cell Rep. 2014;7:353–61.
15. Almeida RD, Loose M, Sottile V, Matsa E, Denning C, Young L, et al. 5-hydroxymethylcytosine enrichment of non-committed cells is not a universal feature of vertebrate development. Epigenetics. 2012;7:383–9.
16. Almeida RD, Sottile V, Loose M, De Sousa PA, Johnson AD, Ruzov A. Semi-quantitative immunohistochemical detection of 5-hydroxymethylcytosine reveals conservation of its tissue distribution between amphibians and mammals. Epigenetics. 2012;7:137–40.
17. Chowdhury B, Cho IH, Hahn N, Iruzayary J. Quantification of 5-methylcytosine, 5-hydroxymethylcytosine and 5-carboxylcytosine from the blood of cancer patients by an enzyme-based immunoassay. Anal Chim Acta. 2014;852:212–7.